Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (FAKHRAVAC®) in healthy adults aged 18–55 years: Randomized, double-blind, placebo-controlled, phase I clinical trial

Autor: Ansarifar, Akram, Farahani, Ramin Hamidi, Rahjerdi, Ahmad Karimi, Ahi, Mohammadreza, Sheidaei, Ali, Gohari, Kimiya, Rahimi, Zahra, Gholami, Fatemeh, Basiri, Pouria, Moradi, Milad, Jahangiri, Arash, Naderi, Kosar, Ghasemi, Soheil, Khatami, Pezhman, Honari, Mohsen, Khodaverdloo, Samane, Shooshtari, Mohammad, Azin, Hajar Mehr, Moradi, Sohrab, Shafaghi, Batool, Allahyari, Hossein, Monazah, Arina, Poor, Ali Khodaei, Bakhshande, Hooman, Taghva, Zahra, Nia, Mohammad Karimi, Dodaran, Masoud Solaymani, Foroughizadeh, Mohsen

Publikováno v: In Vaccine: X December 2023 15

Additional file 2 of Phase II randomized, double blind, placebo controlled, clinical trial of safety and immunogenicity of an inactivated SARS-CoV-2 vaccine FAKHRAVAC in adults aged 18–70 years

Autor: Gholami, Fatemeh, Hamidi Farahani, Ramin, Karimi Rahjerdi, Ahmad, Ahi, Mohammadreza, Sheidaei, Ali, Gohari, Kimiya, Rahimi, Zahra, Ansarifar, Akram, Basiri, Pouria, Moradi, Milad, Jahangiri, Arash, Naderi, Kosar, Ghasemi, Soheil, Khatami, Pezhman, Honari, Mohsen, Khodaverdloo, Samane, Shooshtari, Mohammad, Mehr Azin, Hajar, Moradi, Sohrab, Shafaghi, Batool, Allahyari, Hossein, Monazah, Arina, Khodaei Poor, Ali, Taghva, Zahra, Bakhshande, Hooman, Karimi Nia, Mohammad, Solaymani Dodaran, Masoud, Forooghizade, Mohsen

Additional file 2. Table S12. Changes in laboratories indices of a 43 years old man receiving the placebo. Table S13. Changes in laboratories indices of a 29 years old man receiving the placebo. Table S14. Changes in laboratories indices of a 33 year

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c054c66265a2c66a8a7a7d2035cc6d31

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Development of Inactivated FAKHRAVAC ® Vaccine against SARS-CoV-2 Virus: Preclinical Study in Animal Models.

Autor: Ghasemi, Soheil, Naderi Saffar, Kosar, Ebrahimi, Firooz, Khatami, Pezhman, Monazah, Arina, Alizadeh, Ghorban-Ali, Ettehadi, Hossein-Ali, Rad, Iman, Nojehdehi, Shahrzad, Kehtari, Mousa, Kouhkan, Fatemeh, Barjasteh, Hesam, Moradi, Sohrab, Ghorbani, Mohammad-Hosein, Khodaie, Ali, Papizadeh, Moslem, Najafi, Roghayeh, Naghneh, Ehsan, Sadeghi, Davood, Karimi Rahjerdi, Ahmad

Publikováno v: Vaccines; Nov2021, Vol. 9 Issue 11, p1271, 1p

Phase II randomized, double blind, placebo controlled, clinical trial of safety and immunogenicity of an inactivated SARS-CoV-2 vaccine FAKHRAVAC in adults aged 18-70 years.

Autor: Gholami F; Department of Epidemiology, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.; Clinical Trial Center of Iran University of Medical Sciences, Tehran, Iran., Hamidi Farahani R; AJA University of Medical Sciences, Tehran, Iran., Karimi Rahjerdi A; Milad Daro Noor Pharmaceutical (MDNP) Company IR, Tehran, Iran.; Stem Cell Technology Research Center (STRC), Tehran, Iran., Ahi M; Clinical Trial Center of Iran University of Medical Sciences, Tehran, Iran., Sheidaei A; Clinical Trial Center of Iran University of Medical Sciences, Tehran, Iran., Gohari K; Clinical Trial Center of Iran University of Medical Sciences, Tehran, Iran., Rahimi Z; Clinical Trial Center of Iran University of Medical Sciences, Tehran, Iran., Ansarifar A; Clinical Trial Center of Iran University of Medical Sciences, Tehran, Iran., Basiri P; Milad Daro Noor Pharmaceutical (MDNP) Company IR, Tehran, Iran., Moradi M; Milad Daro Noor Pharmaceutical (MDNP) Company IR, Tehran, Iran., Jahangiri A; Milad Daro Noor Pharmaceutical (MDNP) Company IR, Tehran, Iran., Naderi K; Milad Daro Noor Pharmaceutical (MDNP) Company IR, Tehran, Iran.; Stem Cell Technology Research Center (STRC), Tehran, Iran., Ghasemi S; Milad Daro Noor Pharmaceutical (MDNP) Company IR, Tehran, Iran., Khatami P; Milad Daro Noor Pharmaceutical (MDNP) Company IR, Tehran, Iran., Honari M; Milad Daro Noor Pharmaceutical (MDNP) Company IR, Tehran, Iran., Khodaverdloo S; Milad Daro Noor Pharmaceutical (MDNP) Company IR, Tehran, Iran., Shooshtari M; Milad Daro Noor Pharmaceutical (MDNP) Company IR, Tehran, Iran., Mehr Azin H; Milad Daro Noor Pharmaceutical (MDNP) Company IR, Tehran, Iran., Moradi S; Milad Daro Noor Pharmaceutical (MDNP) Company IR, Tehran, Iran., Shafaghi B; Milad Daro Noor Pharmaceutical (MDNP) Company IR, Tehran, Iran., Allahyari H; Milad Daro Noor Pharmaceutical (MDNP) Company IR, Tehran, Iran., Monazah A; Milad Daro Noor Pharmaceutical (MDNP) Company IR, Tehran, Iran., Khodaei Poor A; Milad Daro Noor Pharmaceutical (MDNP) Company IR, Tehran, Iran., Taghva Z; Milad Daro Noor Pharmaceutical (MDNP) Company IR, Tehran, Iran., Bakhshande H; Clinical Trial Center of Iran University of Medical Sciences, Tehran, Iran., Karimi Nia M; Milad Daro Noor Pharmaceutical (MDNP) Company IR, Tehran, Iran., Solaymani Dodaran M; Clinical Trial Center of Iran University of Medical Sciences, Tehran, Iran., Forooghizade M; Malek Ashtar University of Technology, Tehran, Iran. fakhravacrct@gmail.com.

Publikováno v: BMC infectious diseases [BMC Infect Dis] 2023 Feb 24; Vol. 23 (1), pp. 118. Date of Electronic Publication: 2023 Feb 24.